In this podcast, Dr. Gary Lyman describes biosimilars for cancer treatment and why they are important. He also talks about why ASCO is releasing a statement on them today.
ASCO and NCCN have worked together to help clinicians and patients identify and treat the side effects of immunotherapy before they become dangerous. Doctor and patient advocate Laura Porter describes what to watch out for if you’re taking an immune checkpoint inhibitor, a type of immunotherapy, for cancer.
The 2018 Genitourinary Cancers Symposium includes exciting research that focuses on effective treatment options for kidney cancer, prostate cancer, and bladder cancer.
The 2018 Clinical Cancer Advances report of the American Society of Clinical Oncology has crowned an adoptive cell immunotherapy as its Advance of the Year. What is this innovative cancer treatment? What are the risks and benefits?
“Even after I heard horror stories about the negative effects of indoor tanning, I knew they’d never happen to me. I couldn’t have been more wrong.” Ashley Drury shares her journey from tanning bed advocate to survivor of advanced melanoma.
In this podcast, Cancer.Net Associate Editor Dr. Michael Williams describes lymphoma research advances presented at the American Society of Hematology Annual Meeting.
In this month’s From the Editor’s Desk, Dr. Schapira reviews highlights of 2017 in the world of cancer treatment and care.
Cancer survivor Bryant Wieneke describes his experience receiving immunotherapy to treat metastatic melanoma.
La inmunoterapia ha hecho avances apasionantes en 2015. Dado su potencial, ASCO la nombró el adelanto clínico del año 2016 para el cáncer.
ASCO Annual Meeting 2017: Advances in Immunotherapy for Multiple Myeloma and Mesothelioma, and Targeted Therapies for Non-Small Cell Lung Cancer and HER2-Positive Breast Cancer
Oncology professionals from around the globe are in Chicago for the ASCO Annual Meeting. Today’s key research highlights include CAR T-cell therapy for multiple myeloma, immune checkpoint inhibitors for mesothelioma, and targeted therapy advances for non-small cell lung cancer and HER2-positive breast cancer.